secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2023-09-12T23:59:59+00:00
Accession:  0001193125-23-233448
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 2.01, 3.02, 3.03, 4.01, 5.01, 5.02, 5.03, 5.05, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reverse merger closed: Magenta becomes Dianthus Therapeutics; ticker changes to DNTH
--------------------------------------------------------------------------------

- Merger closed: Magenta combined with Dianthus OpCo; new entity trades as DNTH; ~14.8M shares post-merger.
- OpCo shareholders own ~77% of combined company; Magenta holders get ~23% plus CVRs for potential milestone payments.
- Reverse stock split 1:16 effective pre-merger; prior Magenta share count reduced to ~3.8M.
- New CEO Marino Garcia (ex-OpCo CEO); board reconstituted with 6 OpCo directors; auditor changed to Deloitte.
- OpCo pre-closing financing raised ~$72M through sale of common stock and pre-funded warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312523233448/0001193125-23-233448-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312523233448/d550960d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-233448

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer